Article
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
20 Apr 2022
Abstract excerpt
The implementation of tyrosine kinase inhibitors (TKIs) has dramatically improved the outcome of CML patients with the overall survival approaching general population [ 1 ]. Hence, the achievement of durable treatment-free remission (TFR) after TKI discontinuation has emerged as a new treatment goal [ 2 ]. In several studies, approximately half of CML patients in deep molecular remission (DMR) can successfully...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.